Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of sodium on the fibrillatory potential of ioversol.
Ralston WH, Robbins MS, Mosier LD, Barco SJ, Adams MD, Hopkins RM. Ralston WH, et al. Among authors: barco sj. Invest Radiol. 1988 Sep;23 Suppl 1:S140-3. doi: 10.1097/00004424-198809001-00020. Invest Radiol. 1988. PMID: 3198334
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
Barco S, Schmidtmann I, Ageno W, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jiménez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Manolis A, Meyer A, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Westerweel PE, Wild PS, Konstantinides SV, Lankeit M; HoT-PE Investigators. Barco S, et al. Eur Heart J. 2020 Jan 21;41(4):509-518. doi: 10.1093/eurheartj/ehz367. Eur Heart J. 2020. PMID: 31120118 Clinical Trial.
Survival and quality of life after early discharge in low-risk pulmonary embolism.
Barco S, Schmidtmann I, Ageno W, Anušić T, Bauersachs RM, Becattini C, Bernardi E, Beyer-Westendorf J, Bonacchini L, Brachmann J, Christ M, Czihal M, Duerschmied D, Empen K, Espinola-Klein C, Ficker JH, Fonseca C, Genth-Zotz S, Jiménez D, Harjola VP, Held M, Iogna Prat L, Lange TJ, Lankeit M, Manolis A, Meyer A, Münzel T, Mustonen P, Rauch-Kroehnert U, Ruiz-Artacho P, Schellong S, Schwaiblmair M, Stahrenberg R, Valerio L, Westerweel PE, Wild PS, Konstantinides SV; HoT-PE Investigators; HoT-PE Trial Investigators are:. Barco S, et al. Eur Respir J. 2021 Feb 4;57(2):2002368. doi: 10.1183/13993003.02368-2020. Print 2021 Feb. Eur Respir J. 2021. PMID: 32859673 Free article.
Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Rationale and design of the HoT-PE Trial.
Barco S, Lankeit M, Binder H, Schellong S, Christ M, Beyer-Westendorf J, Duerschmied D, Bauersachs R, Empen K, Held M, Schwaiblmair M, Fonseca C, Jiménez D, Becattini C, Quitzau K, Konstantinides S. Barco S, et al. Thromb Haemost. 2016 Jul 4;116(1):191-7. doi: 10.1160/TH16-01-0004. Epub 2016 Mar 24. Thromb Haemost. 2016. PMID: 27010343 Clinical Trial.
Risk-adapted management of pulmonary embolism.
Barco S, Konstantinides SV. Barco S, et al. Thromb Res. 2017 Mar;151 Suppl 1:S92-S96. doi: 10.1016/S0049-3848(17)30076-2. Thromb Res. 2017. PMID: 28262244 Review.
Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study.
Klok FA, Ageno W, Barco S, Binder H, Brenner B, Duerschmied D, Empen K, Faggiano P, Ficker JH, Galiè N, Ghuysen A, Held M, Heydenreich N, Huisman MV, Jiménez D, Kozak M, Lang IM, Lankeit M, Münzel T, Petris A, Pruszczyk P, Quitzau K, Schellong S, Schmidt KH, Stefanovic BS, Verschuren F, Wolf-Puetz A, Meyer G, Konstantinides SV; PEITHO-2 Investigators. Klok FA, et al. Thromb Haemost. 2017 Dec;117(12):2425-2434. doi: 10.1160/TH17-06-0434. Epub 2017 Dec 6. Thromb Haemost. 2017. PMID: 29212130
168 results